COMPUGEN LTD (CGEN)
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
Compugen Ltd.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 18, 2026 | 2.00 | 2.02 | 1.97 | 1.97 | 132,019 |
| Nov 17, 2026 | 1.99 | 2.05 | 1.98 | 2.02 | 197,679 |
| Nov 16, 2026 | 2.06 | 2.07 | 2.00 | 2.04 | 250,429 |
| Nov 13, 2026 | 2.11 | 2.12 | 2.04 | 2.10 | 209,644 |
| Nov 12, 2026 | 2.04 | 2.14 | 2.04 | 2.12 | 190,239 |
| Nov 11, 2026 | 2.09 | 2.12 | 2.07 | 2.09 | 211,132 |
| Nov 10, 2026 | 2.13 | 2.14 | 2.03 | 2.09 | 214,917 |
| Nov 9, 2026 | 1.96 | 2.15 | 1.96 | 2.14 | 290,497 |
| Nov 6, 2026 | 1.88 | 1.97 | 1.88 | 1.96 | 183,992 |
| Nov 5, 2026 | 2.00 | 2.00 | 1.86 | 1.92 | 299,932 |
| Nov 4, 2026 | 2.03 | 2.05 | 1.98 | 2.03 | 202,920 |
| Nov 3, 2026 | 1.98 | 2.04 | 1.98 | 2.01 | 212,670 |
| Nov 2, 2026 | 1.97 | 2.00 | 1.96 | 1.98 | 151,473 |
| Oct 30, 2026 | 2.02 | 2.02 | 1.92 | 1.98 | 255,459 |
| Oct 29, 2026 | 2.02 | 2.07 | 2.00 | 2.04 | 142,900 |
| Oct 28, 2026 | 1.96 | 2.01 | 1.96 | 2.01 | 149,269 |
| Oct 27, 2026 | 1.92 | 1.97 | 1.88 | 1.97 | 131,409 |
| Oct 26, 2026 | 1.95 | 1.98 | 1.87 | 1.88 | 334,470 |
| Oct 23, 2026 | 1.97 | 1.97 | 1.89 | 1.94 | 148,021 |
| Oct 22, 2026 | 2.11 | 2.14 | 1.92 | 1.96 | 285,546 |
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Chief Financial Officer | Grant/Award | 19.5K | -- | Jul 29, 2026 | |
| Director | Grant/Award | 10.0K | -- | Jul 29, 2026 | |
| Director | Grant/Award | 10.0K | -- | Jul 29, 2026 | |
| Director | Grant/Award | 10.0K | -- | Jul 29, 2026 | |
| Chief Medical Officer | Grant/Award | 18.0K | -- | Jul 29, 2026 | |
| Director | Grant/Award | 10.0K | -- | Jul 29, 2026 |
| Name | Shares | % | Source |
|---|---|---|---|
SILVERARC CAPITAL MANAGEMENT, LLC | 3.6M | 3.8% | 13F |
RENAISSANCE TECHNOLOGIES LLC | 1.5M | 1.6% | 13F |
NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | 1.0M | 1.1% | 13F |
MORGAN STANLEY | 970.6K | 1.0% | 13F |
ARK Investment Management LLC | 887.9K | 0.9% | 13F |
Taylor Frigon Capital Management LLC | 816.3K | 0.9% | 13F |
TWO SIGMA INVESTMENTS, LP | 509.6K | 0.5% | 13F |
Atom Investors LP | 472.9K | 0.5% | 13F |
Altshuler Shaham Ltd | 450.6K | 0.5% | 13F |
STATE STREET CORP | 434.5K | 0.5% | 13F |
Insiders
- Silberman DavidChief Financial Officer
- ZWEIFACH SANFORD SDirector
- Halevy GileadDirector
- Hukkelhoven MathiasDirector
- Mahler MichelleChief Medical Officer
- Livnat Savitzky KinneretDirector
- Kredo Russo SharonSVP, Research & Discovery
- Perry EranDirector
- Cohen-Dayag AnatDirector
- Levine ZuritSVP, Business Development
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe.
The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I clinical study in patients with advanced malignancies as a monotherapy; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with solid tumors; and AZD2936, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase I/II clinical study in patients with advanced or metastatic non-small cell lung cancer.
Its therapeutic pipeline also includes early-stage immuno-oncology programs focused primarily on myeloid targets.
The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets.
It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.
based on 94.73M shares outstanding
30d Avg
241.12K
60d Avg
211.65K
90d Avg
226.95K
Signal8's dilution snapshot of CGEN as of Dec 31, 2025 records an effective F-3 shelf registration (effective Jun 8, 2026) and an at-the-market sales agreement dated Jan 31, 2023, from SEC filings. Compugen Ltd (NASDAQ: CGEN) traded at $1.97 on Nov 18, 2026, down 2.72% from the previous close of $2.02. 52-week range: $1.43 to $3.24. The company is in the Healthcare sector (Biotechnology).